Carol Burt has served as a ResMed director since November 2013 and is chair of the audit and compliance oversight committees. She is also a member of the nominating and governance committee.
Ms. Burt, principal of Burt-Hilliard Investments is a private investor with more than 35 years experience in corporate governance, operations, strategy, finance, mergers and acquisition and investment banking. Since 2013, Ms. Burt has served as a senior advisor and a member of the operating council of Consonance Capital Partners, a New York-based private equity firm focused on investments in the healthcare industry. Ms. Burt serves on the boards of IQVIA Holdings Inc. (NYSE: IQV), where she is a member of the audit committee and leadership development and compensation committee; and two private companies, Global Medical Response and WellDyne.
Prior to their sale, Ms. Burt served on the public boards of Envision Healthcare, Transitional Hospitals, Vanguard Health Systems, WellCare Health Plans, and private-equity-backed KEPRO.
Ms. Burt was formerly senior vice president corporate finance and development of WellPoint, Inc. (now Anthem, Inc.) where she was part of the executive team that built WellPoint from a single state health plan to one of the leading health benefits companies in the US. Ms. Burt was responsible for, among other things, corporate strategic planning and execution, mergers and acquisitions, strategic and venture investments, financial reporting, budgeting and forecasting, treasury, business information systems and real estate management. In addition, WellPoint’s financial services and international insurance business units reported to her.
Before WellPoint, Ms. Burt was senior vice president and treasurer of American Medical Response. Previously, she spent 16 years at Chase Securities, Inc., now JP Morgan Chase & Co (NYSE: JPM), most recently as founder, managing director and head of the Health Care Banking Group.
Ms. Burt is a member of Women Corporate Directors and the International Women’s Forum. Her philanthropic activities focus on mentoring women for leadership positions and environmental causes.
Ms. Burt graduated magna cum laude from the University of Houston, earning a Bachelor of Business Administration.
Ms. Burt’s executive management and board experience in the health insurance, healthcare services, medical technology and financial services industries led the board to the conclusion that she should serve as a director.
What is Carol Burt's net worth?
The estimated net worth of Carol Burt is at least $2.04 million as of May 8th, 2017. Ms. Burt owns 8,447 shares of ResMed stock worth more than $2,040,373 as of November 20th. This net worth approximation does not reflect any other investments that Ms. Burt may own. Learn More about Carol Burt's net worth.
How do I contact Carol Burt?
Has Carol Burt been buying or selling shares of ResMed?
Carol Burt has not been actively trading shares of ResMed over the course of the past ninety days. Most recently, Carol Burt sold 1,500 shares of the business's stock in a transaction on Monday, November 22nd. The shares were sold at an average price of $260.00, for a transaction totalling $390,000.00. Learn More on Carol Burt's trading history.
Who are ResMed's active insiders?
ResMed's insider roster includes Carol Burt (Director), Jan De Witte (Director), Robert Douglas (COO), Karen Drexler (Director), Michael Farrell (CEO), Peter Farrell (Director), Kaushik Ghoshal (Insider), James Hollingshead (Insider), Justin Leong (Insider), David Pendarvis (Insider), Michael Rider (General Counsel), Brett Sandercock (CFO), Rajwant Sodhi (Insider), and Ronald Taylor (Director). Learn More on ResMed's active insiders.
Are insiders buying or selling shares of ResMed?
In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 187,789 shares worth more than $41,061,987.20. The most recent insider tranaction occured on November, 12th when Director Witte Jan De sold 796 shares worth more than $198,052.76. Insiders at ResMed own 0.7% of the company.
Learn More about insider trades at ResMed. Information on this page was last updated on 11/12/2024.
